With their advanced Adeno-Associated Virus platform, nVector enables and accelerates breakthrough gene therapies for conditions like Alzheimer's, Parkinson's, Traumatic Brain Injury, ALS, and other CNS diseases. Their proprietary GreenGlia Technology allows for precise targeting of specific glia and neuron cells, opening up new possibilities for treatment. The nVector Platform offers a Capsid Design Library, allowing for customized viral capsids to meet individual needs, and a Therapeutic Pipeline focused on developing treatments for ALS, Huntington's, Parkinson's, and more.

Additionally, nVector provides clinical assays for ALS diagnosis and customized biomarker testing and development for the CNS. With nVector, the future of CNS treatment is brighter than ever before. Contact nVector today to learn more about their cutting-edge solutions